Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma.
about
Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potentialRole of the tumor microenvironment in mature B-cell lymphoid malignanciesThe Role of Autologous and Allogeneic Stem Cell Transplantation in Follicular Lymphoma in The New Drugs EraNovel Drugs in Follicular LymphomaSafety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial.Idelalisib in the management of lymphoma.Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.Idelalisib for the treatment of non-Hodgkin lymphoma.Novelties in the management of B-cell malignancies: B-cell receptor signaling inhibitors and lenalidomide.Small Molecule Inhibitors in Chronic Lymphocytic Lymphoma and B Cell Non-Hodgkin Lymphoma.Breakthrough therapies in B-cell non-Hodgkin lymphoma.Targeted therapy in the treatment of chronic lymphocytic leukemia: facts, shortcomings and hopes for the future.Targeting of B-cell receptor signalling in B-cell malignancies.Clinical experience with lenalidomide alone or in combination with rituximab in indolent B-cell and mantle cell lymphomas.Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.Clinical Trials in the Genomic Era.The landscape of new drugs in lymphomaClinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow.Current Treatment of Chronic Lymphocytic Leukemia.Follicular lymphoma: State-of-the-art ICML workshop in Lugano 2015.PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.DNA Methylation Events as Markers for Diagnosis and Management of Acute Myeloid Leukemia and Myelodysplastic Syndrome.Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model.The PI3K Pathway in Human Disease.Title: Rituximab: A Benchmark in the Development of Chemotherapy-free Treatment Strategies for Follicular Lymphomas.The evolving role of targeted biological agents in the management of indolent B-cell lymphomas.Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib
P2860
Q26747753-E58513E0-EDCC-4147-BDDC-FC1308A33F47Q26748775-798ED575-2A4A-4B98-B21B-EF933B833B7FQ28072397-90FF7726-075F-42C5-AE54-42F7065B33E8Q28076335-303F6AA9-04AF-4D4E-994E-4CA39CF97D39Q33429161-C563A491-EAB4-4279-B201-6B28D4CF2B46Q34529311-B27751E6-5687-49A7-85E3-3AFCB05427C3Q37079141-29B43AB7-0129-49CB-9759-115D3DFAE892Q37114445-403DC5C9-70B6-4396-AF53-560D9E657678Q38594364-280BF40B-44B4-460B-89C6-34EBD2772D22Q38691282-150216F1-6337-4DC8-8063-6F8A14931770Q38708600-1F5340BA-0468-454E-A4CC-CF4040FDE85DQ38738661-B6156C39-EFB1-44B8-8875-5CF0F5572D55Q38744922-C837C104-CE96-4537-B14D-13475C9F507AQ38800049-EEEEE815-9EB2-4D1A-95FD-19E09AF7054EQ38850667-1AA8E77F-9A79-40E6-B0A0-F33E2D180698Q38897083-B5C45099-C7F4-4930-8A72-55A3B8A3B0D5Q38905607-ECE8CFF8-6192-4F10-9085-C96955BFE06CQ39061630-911A881F-2C8B-4B4E-827D-1A3F455536D2Q39098904-B9FEAEA5-8F21-4578-BBA5-2CA6DA3A865EQ39129372-A370B8D5-A1B9-416D-A518-D4BABF21F4CBQ39221094-BAEBFA3C-C1DF-4799-A533-5EE929A4A223Q41994564-F72B7BFD-96C0-493C-AF9E-45E4C91E2CEFQ42361215-ECFA5C2A-4988-4800-870B-BC5EF9F74D7DQ46074725-10EADE25-A7D9-469D-8929-5EF7DE5785F9Q46546002-1D98F4CC-5FA5-430B-8CEA-2CB22A6E3943Q47365893-E8150806-D235-4C3B-9484-C0607298200FQ49226138-E891C1F1-3874-4B18-8802-B444277DA32FQ58729853-1571E5DB-6A09-4CEC-AD17-F7D2132BDB95
P2860
Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Lenalidomide, idelalisib, and ...... /refractory indolent lymphoma.
@en
Lenalidomide, idelalisib, and ...... /refractory indolent lymphoma.
@nl
type
label
Lenalidomide, idelalisib, and ...... /refractory indolent lymphoma.
@en
Lenalidomide, idelalisib, and ...... /refractory indolent lymphoma.
@nl
prefLabel
Lenalidomide, idelalisib, and ...... /refractory indolent lymphoma.
@en
Lenalidomide, idelalisib, and ...... /refractory indolent lymphoma.
@nl
P2093
P2860
P1433
P1476
Lenalidomide, idelalisib, and ...... d/refractory indolent lymphoma
@en
P2093
Nathan H Fowler
Sattva S Neelapu
Sheryl G Forbes
Yasuhiro Oki
P2860
P304
P356
10.1182/BLOOD-2015-03-633156
P407
P577
2015-05-01T00:00:00Z